PMID- 12152994
OWN - NLM
STAT- MEDLINE
DCOM- 20030113
LR  - 20191106
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 43
IP  - 6
DP  - 2002 Jun
TI  - Follow-up of minimal residual disease in pediatric acute myeloblastic leukemia 
      using metaphase-FISH.
PG  - 1261-5
AB  - In acute myeloblastic leukemia (AML) the follow-up of minimal residual disease 
      (MRD) has focused on specific chromosomal aberrations (e.g. t(15;17), t(8;21), 
      inv16/t(16;16)) mostly employing reverse transcriptase-PCR. High or increasing 
      levels of MRD are associated with an increased risk of relapse but low levels may 
      persist in patients with prolonged or even durable remission. In adult patients 
      with AML the increased risk of relapse has also been demonstrated using flow 
      cytometry and fluorescence in situ hybridization (FISH). We evaluated the 
      presence of MRD among pediatric patients with AML during and after the cessation 
      of therapy. We were able to establish a clonal marker for the follow-up in 80% of 
      our cases; 11 of the 15 with a clonal marker had detectable MRD at some point 
      during follow-up while 4/15 relapsed 12-14 months after diagnosis. In two there 
      was hematological relapse preceded by an increase in their FISH-detectable number 
      of clonal cells. In 7 of the 11 remaining in CR1 there were small (< 1%) numbers 
      of clonal cells detectable at one or more time-points. Out of the group of 15 
      pediatric patients with AML, 12 are currently alive in CCR with a median 
      follow-up of 44 months (range 7-63 months). Our data establish the role of 
      metaphase-FISH in the follow-up of AML in children and emphasize the importance 
      of an increasing level of MRD in predicting a relapse. Yet, low and stable levels 
      of marrow MRD a ppear compatible with CCR.
FAU - Vettenranta, K
AU  - Vettenranta K
AD  - Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for 
      Children and Adolescents, University of Helsinki, Finland. kim.vettenranta@hus.fi
FAU - Autio, K
AU  - Autio K
FAU - Hovi, L
AU  - Hovi L
FAU - Knuutila, S
AU  - Knuutila S
FAU - Saarinen-Pihkala, U M
AU  - Saarinen-Pihkala UM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Aneuploidy
MH  - Bone Marrow/pathology
MH  - Child
MH  - Child, Preschool
MH  - *Chromosome Aberrations
MH  - Chromosomes, Human/genetics/*ultrastructure
MH  - Clone Cells/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Infant
MH  - Leukemia, Myeloid/genetics/*pathology
MH  - Male
MH  - Metaphase
MH  - Neoplasm, Residual
MH  - Recurrence
MH  - Remission Induction
MH  - Sensitivity and Specificity
EDAT- 2002/08/03 10:00
MHDA- 2003/01/14 04:00
CRDT- 2002/08/03 10:00
PHST- 2002/08/03 10:00 [pubmed]
PHST- 2003/01/14 04:00 [medline]
PHST- 2002/08/03 10:00 [entrez]
AID - 10.1080/10428190290026312 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2002 Jun;43(6):1261-5. doi: 10.1080/10428190290026312.